Skip to main content
Top
Published in: Social Psychiatry and Psychiatric Epidemiology 12/2013

01-12-2013 | Original Paper

Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan

Authors: Yuan-Chang Hsu, I-Chia Chien, Happy Kuy-Lok Tan, Ching-Heng Lin, Shu-Wen Cheng, Yiing-Jenq Chou, Pesus Chou

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 12/2013

Login to get access

Abstract

Purpose

We used Taiwan’s population-based National Health Insurance database to investigate the trends, correlates, and disease patterns of antipsychotic use among children and adolescents.

Methods

The National Health Research Institutes provided a database of 1,000,000 random subjects for study. We chose subjects who were aged 18 years or younger during 1997–2005. In this sample, subjects who were given at least one antipsychotic prescription, including first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs), were identified. Trends, prevalence, and associated factors of antipsychotic use were determined. The proportion of antipsychotic use for psychiatric and medical disorders was also analyzed.

Results

The 1-year prevalence of SGA use increased from 0.00 % in 1997 to 0.09 % in 2005, whereas the 1-year prevalence of FGA use ranged from 2.24 to 3.43 % during this same period, with no significant change. Age and male gender were associated with higher SGA use. Among SGA users, the greatest proportion suffered from psychiatric disorders, including tics, hyperkinetic syndrome of childhood, schizophrenia, affective disorders, and autism. Among FGA users, a larger proportion was for medical conditions, including diseases of the digestive and respiratory systems.

Conclusion

The prevalence of pediatric SGA use increased greatly from 1997 to 2005. Among pediatric subjects using antipsychotics, SGAs were mostly used for psychiatric disorders, whereas FGAs were mostly prescribed for medical conditions. Future research will focus on indication, dosage, frequency, duration, adverse effects, and off-label use of antipsychotics in the pediatric population.
Literature
1.
go back to reference Verdoux H, Tournier M, Begaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121:4–10PubMedCrossRef Verdoux H, Tournier M, Begaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121:4–10PubMedCrossRef
2.
go back to reference Pathak P, West D, Martin BC, Helm ME, Henderson C (2010) Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001–2005. Psychiatr Serv 61:123–129PubMedCrossRef Pathak P, West D, Martin BC, Helm ME, Henderson C (2010) Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001–2005. Psychiatr Serv 61:123–129PubMedCrossRef
3.
go back to reference Hsia YF, Maclennan K (2009) Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK. Eur J Epidemiol 24:211–216PubMedCrossRef Hsia YF, Maclennan K (2009) Rise in psychotropic drug prescribing in children and adolescents during 1992–2001: a population-based study in the UK. Eur J Epidemiol 24:211–216PubMedCrossRef
4.
go back to reference Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679–685PubMedCrossRef Olfson M, Blanco C, Liu L, Moreno C, Laje G (2006) National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679–685PubMedCrossRef
5.
go back to reference Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML (2002) Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 12:221–229PubMedCrossRef Patel NC, Sanchez RJ, Johnsrud MT, Crismon ML (2002) Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000. J Child Adolesc Psychopharmacol 12:221–229PubMedCrossRef
6.
go back to reference Pringsheim T, Lam D, Patten SB (2011) The Pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol 21:537–543PubMedCrossRef Pringsheim T, Lam D, Patten SB (2011) The Pharmacoepidemiology of antipsychotic medications for Canadian children and adolescents: 2005–2009. J Child Adolesc Psychopharmacol 21:537–543PubMedCrossRef
7.
go back to reference Clavenna A, Rossi E, DeRosa M, Bonati M (2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 166:339–347PubMedCrossRef Clavenna A, Rossi E, DeRosa M, Bonati M (2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 166:339–347PubMedCrossRef
8.
go back to reference Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH (2010) First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 19:124–137PubMed Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH (2010) First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 19:124–137PubMed
9.
go back to reference Aparasu RR, Bhatara V (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents 2003–2004. Curr Med Res Opin 23:49–56PubMedCrossRef Aparasu RR, Bhatara V (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents 2003–2004. Curr Med Res Opin 23:49–56PubMedCrossRef
10.
go back to reference Aparasu RR, Bhatara V (2005) Antipsychotic prescribing trends among youths, 1997–2002. Psychiatric Serv 56:904CrossRef Aparasu RR, Bhatara V (2005) Antipsychotic prescribing trends among youths, 1997–2002. Psychiatric Serv 56:904CrossRef
11.
go back to reference Koelch M, Prestel A, Singer H, Keller F, Fegert JM, Schlack R, Hoelling H, Knopf H (2009) Psychotropic medication in children and adolescents in Germany: prevalence indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 19:765–770PubMedCrossRef Koelch M, Prestel A, Singer H, Keller F, Fegert JM, Schlack R, Hoelling H, Knopf H (2009) Psychotropic medication in children and adolescents in Germany: prevalence indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 19:765–770PubMedCrossRef
12.
go back to reference Doey T, Handelman K, Seabrook JA, Steele M (2007) Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry 52:363–368PubMed Doey T, Handelman K, Seabrook JA, Steele M (2007) Survey of atypical antipsychotic prescribing by Canadian child psychiatrists and developmental pediatricians for patients aged under 18 years. Can J Psychiatry 52:363–368PubMed
13.
go back to reference Chien IC, Hsu JH, Bih SH, Lin CH, Chou YJ, Lee CH, Chou P (2008) Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin Neurosci 62:677–684PubMedCrossRef Chien IC, Hsu JH, Bih SH, Lin CH, Chou YJ, Lee CH, Chou P (2008) Prevalence, correlates, and disease patterns of antipsychotic use in Taiwan. Psychiatry Clin Neurosci 62:677–684PubMedCrossRef
14.
go back to reference Chien IC, Hsu YC, Tan HK, Lin CH, Cheng SW, Chou YJ, Chou P (2012) Trends, correlates, and disease patterns of antidepressant use among children and adolescents in Taiwan. J Child Neurol. [Epub ahead of print] Chien IC, Hsu YC, Tan HK, Lin CH, Cheng SW, Chou YJ, Chou P (2012) Trends, correlates, and disease patterns of antidepressant use among children and adolescents in Taiwan. J Child Neurol. [Epub ahead of print]
15.
go back to reference Chien IC, Chou YJ, Lin CH, Bih SH, Chou P (2004) Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv 55:691–697PubMedCrossRef Chien IC, Chou YJ, Lin CH, Bih SH, Chou P (2004) Prevalence of psychiatric disorders among National Health Insurance enrollees in Taiwan. Psychiatr Serv 55:691–697PubMedCrossRef
16.
go back to reference Chien IC, Bih SH, Lin CH, Chou YJ, Lee WG, Lee CH, Chou P (2011) Correlates and psychiatric disorders associated with psychotropic drug use in Taiwan. Soc Psychiatry Psychiatr Epidemiol 46:77–84PubMedCrossRef Chien IC, Bih SH, Lin CH, Chou YJ, Lee WG, Lee CH, Chou P (2011) Correlates and psychiatric disorders associated with psychotropic drug use in Taiwan. Soc Psychiatry Psychiatr Epidemiol 46:77–84PubMedCrossRef
17.
go back to reference Rani F, Murray ML, Byrne PJ, Wong ICK (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002–1009PubMedCrossRef Rani F, Murray ML, Byrne PJ, Wong ICK (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121:1002–1009PubMedCrossRef
18.
go back to reference Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents focus on pharmacotherapy. Drugs 71:179–208PubMedCrossRef Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents focus on pharmacotherapy. Drugs 71:179–208PubMedCrossRef
19.
go back to reference Almandil NB, Wong IC (2011) Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed 96:192–196PubMedCrossRef Almandil NB, Wong IC (2011) Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed 96:192–196PubMedCrossRef
20.
go back to reference Pringsheim T, Panagiotopoulos C, Davidson J, Ho J (2011) Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 20:218–233PubMed Pringsheim T, Panagiotopoulos C, Davidson J, Ho J (2011) Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry 20:218–233PubMed
21.
go back to reference Correll CU, Kratochvil CJ, March JS (2011) Developments in pediatric psychopharmacology: focus on stimulants, antidepressants and antipsychotics. J Clin Psychiatry 72:655–670PubMedCrossRef Correll CU, Kratochvil CJ, March JS (2011) Developments in pediatric psychopharmacology: focus on stimulants, antidepressants and antipsychotics. J Clin Psychiatry 72:655–670PubMedCrossRef
22.
go back to reference Findling RL, McNamara NK (2004) Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65:30–44PubMed Findling RL, McNamara NK (2004) Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 65:30–44PubMed
23.
go back to reference Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N (2012) Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 129:e771–e784PubMedCrossRef Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, Vandermeer B, Dryden DM, Carrey N (2012) Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics 129:e771–e784PubMedCrossRef
24.
go back to reference Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21:600–620PubMedCrossRef Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21:600–620PubMedCrossRef
25.
go back to reference Patel NC, Crismon ML, Shafer A (2006) Diagnosis and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother 40:205–211PubMedCrossRef Patel NC, Crismon ML, Shafer A (2006) Diagnosis and antipsychotic treatment among youths in a public mental health system. Ann Pharmacother 40:205–211PubMedCrossRef
26.
go back to reference Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR, Faraone SV, Biederman J (2011) Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50:749–762PubMedCrossRef Liu HY, Potter MP, Woodworth KY, Yorks DM, Petty CR, Wozniak JR, Faraone SV, Biederman J (2011) Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50:749–762PubMedCrossRef
27.
go back to reference Findling RL, Steiner H, Weller EB (2005) Use of antipsychotic in child and adolescents. J Clin Psychiatry 66:29–40PubMed Findling RL, Steiner H, Weller EB (2005) Use of antipsychotic in child and adolescents. J Clin Psychiatry 66:29–40PubMed
28.
go back to reference McDougle CJ, Stigler KA, Erickson CA, Posey DJ (2008) Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69:15–20PubMedCrossRef McDougle CJ, Stigler KA, Erickson CA, Posey DJ (2008) Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 69:15–20PubMedCrossRef
29.
go back to reference Chien IC, Lin CH, Chou YJ, Chou P (2012) Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996–2005: a national population-based study. Soc Psychiatry Psychiatr Epidemiol 47:1885–1890PubMedCrossRef Chien IC, Lin CH, Chou YJ, Chou P (2012) Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996–2005: a national population-based study. Soc Psychiatry Psychiatr Epidemiol 47:1885–1890PubMedCrossRef
30.
go back to reference Fullerton CA, Epstein AM, Frank RG, Normand SLT, Fu CX, McGuire TG (2012) Medication use and spending trends among children with ADHD in Florida’s medicaid program, 1996–2005. Psychiatr Serv 63:115–121PubMedCrossRef Fullerton CA, Epstein AM, Frank RG, Normand SLT, Fu CX, McGuire TG (2012) Medication use and spending trends among children with ADHD in Florida’s medicaid program, 1996–2005. Psychiatr Serv 63:115–121PubMedCrossRef
31.
go back to reference Tcheremissine OV, Lieving Lori M (2006) Pharmacological aspects of the treatment of conduct disorder in children and adolescents. CNS Drug 20:549–565CrossRef Tcheremissine OV, Lieving Lori M (2006) Pharmacological aspects of the treatment of conduct disorder in children and adolescents. CNS Drug 20:549–565CrossRef
32.
go back to reference Storch EA, Lewin AB, Geffken GR, Morgan JR, Murphy TK (2010) The role of comorbid disruptive behavior in the clinical expression of pediatric obsessive-compulsive disorder. Behav Res Ther 48:1204–1210PubMedCrossRef Storch EA, Lewin AB, Geffken GR, Morgan JR, Murphy TK (2010) The role of comorbid disruptive behavior in the clinical expression of pediatric obsessive-compulsive disorder. Behav Res Ther 48:1204–1210PubMedCrossRef
33.
go back to reference Aman MG, Gharabawi GM (2004) Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics with an emphasis on Risperidone. J Clin Psychiatry 65:1197–1210PubMedCrossRef Aman MG, Gharabawi GM (2004) Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics with an emphasis on Risperidone. J Clin Psychiatry 65:1197–1210PubMedCrossRef
34.
go back to reference Antochi R, Stavrakaki Emery PC (2003) Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Postgrad Med J 79:139–146PubMedCrossRef Antochi R, Stavrakaki Emery PC (2003) Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Postgrad Med J 79:139–146PubMedCrossRef
35.
go back to reference Handen BL, Gilchrist R (2006) Practitioner review: psychopharmacology in children and adolescents with mental retardation. J Child Psychol Psychiatry 47:871–882PubMedCrossRef Handen BL, Gilchrist R (2006) Practitioner review: psychopharmacology in children and adolescents with mental retardation. J Child Psychol Psychiatry 47:871–882PubMedCrossRef
36.
go back to reference Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf 20:177–184PubMedCrossRef Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf 20:177–184PubMedCrossRef
37.
go back to reference Hert MD, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 26:144–158PubMedCrossRef Hert MD, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 26:144–158PubMedCrossRef
38.
go back to reference Maayan L, ChCorrell CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517–535PubMedCrossRef Maayan L, ChCorrell CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517–535PubMedCrossRef
39.
go back to reference Rani FA, Byrne PF, Murray ML, Carter P, Wong ICK (2009) Paediatric atypical antipsychotic monitoring safety (PAMS) study. Drug Safe 32:325–333CrossRef Rani FA, Byrne PF, Murray ML, Carter P, Wong ICK (2009) Paediatric atypical antipsychotic monitoring safety (PAMS) study. Drug Safe 32:325–333CrossRef
40.
go back to reference Caccia S, Clavenna A, Bonati M (2011) Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 7:591–608PubMedCrossRef Caccia S, Clavenna A, Bonati M (2011) Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 7:591–608PubMedCrossRef
41.
go back to reference Capone GT, Goyal P, Grados M, Smith B, Kammann H (2008) Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr 29:106–116PubMedCrossRef Capone GT, Goyal P, Grados M, Smith B, Kammann H (2008) Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study. J Dev Behav Pediatr 29:106–116PubMedCrossRef
42.
go back to reference Findling RL (2008) Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 69:9–14PubMedCrossRef Findling RL (2008) Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 69:9–14PubMedCrossRef
Metadata
Title
Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan
Authors
Yuan-Chang Hsu
I-Chia Chien
Happy Kuy-Lok Tan
Ching-Heng Lin
Shu-Wen Cheng
Yiing-Jenq Chou
Pesus Chou
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 12/2013
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-013-0702-2

Other articles of this Issue 12/2013

Social Psychiatry and Psychiatric Epidemiology 12/2013 Go to the issue